InvestorNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy
February 11, 2026
LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is focused on enhancing established cancer therapies by targeting a fundamental biological pathway involved in tumor survival and resistance. “Rather than developing standalone treatments, LIXTE is advancing a first-in-class approach designed to increase the effectiveness of chemotherapy and immunotherapy across multiple cancer indications,” reads a recent […]
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Aligns Liora and the LiGHT System With LB-100 to Push the Frontier of Cancer Treatment
February 9, 2026
LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, a company that’s pioneering proton therapy systems for treating tumors in various types of cancers. Liora is becoming a wholly owned subsidiary of LIXTE, and the acquisition also includes Liora’s proprietary flagship technology, the LiGHT System (Linac for Image Guided Hadron Therapy), […]
InvestorNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment
February 6, 2026
LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is leading efforts in addressing some of the pressing challenges in cancer treatment. “Instead of developing standalone cancer drugs, the company is adopting a different strategy aimed at enhancing the overall effectiveness of existing immunotherapy and chemotherapy regimens through a novel biological target,” reads a recent […]
Improving the Odds: How LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is Working to Make Cancer Therapies More Effective
February 4, 2026
Despite decades of progress in oncology, many cancers remain resistant to treatment, not because therapies are unavailable, but because tumor cells adapt. Immunotherapies and chemotherapies can produce meaningful responses, yet durability and consistency remain challenges, particularly in aggressive or rare cancer subtypes. Increasingly, research is shifting toward approaches that improve how well existing treatments work, […]
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances a Novel Approach to Enhancing Cancer Therapy
January 22, 2026
LIXTE Biotechnology (NASDAQ: LIXT) is a clinical-stage pharmaceutical company leading efforts in addressing some of the pressing challenges in cancer treatment. Instead of developing standalone cancer drugs, the company is adopting a different strategy aimed at enhancing the overall effectiveness of existing immunotherapy and chemotherapy regimens through a novel biological target. LIXTE’s platform is built […]
InvestorNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Sponsors Good Health Mind, Body and Soul Summit at Morehouse College
January 21, 2026
LIXTE Biotechnology Holdings (NASDAQ: LIXT) is sponsoring the inaugural Good Health: Mind, Body & Soul Summit, an invitation-only event inspired by the music, legacy, and lived experiences of De La Soul and scheduled for Feb. 19 at Morehouse College in Atlanta. The Summit brings together leaders in health, culture, science, and community to advance health equity […]
InvestorNewsBreaks – Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) to Participate In DealFlow Discovery Conference
January 20, 2026
Lixte Biotechnology Holdings (NASDAQ: LIXT) announced it will participate in the DealFlow Discovery Conference to be held Jan. 28–29, 2026, in Atlantic City, N.J. The company said Chief Executive Officer Geordan Pursglove will conduct one-on-one meetings with investors during the conference as LIXTE continues advancing LB-100, its first-in-class inhibitor of protein phosphatase 2A, through clinical development. To view the full press release, visit https://ibn.fm/F1dlA About Lixte Biotechnology Holdings, Inc. LIXTE Biotechnology Holdings, […]
InvestorNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Engages IBN to Support Corporate Communications Strategy
January 13, 2026
LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company focused on advancing differentiated cancer therapies, announced that it has engaged IBN, a multifaceted financial news and publishing company, to support its corporate communications strategy. Through the engagement, IBN will leverage its investor-focused distribution platform, including more than 5,000 syndication outlets, newsletters, social media channels, blogs […]
IBN Initiates Coverage of LIXTE Biotechnology Holdings Inc.
January 13, 2026
AUSTIN, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) — via IBN – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a biotech company focused on advancing cancer treatments, has engaged IBN, a multifaceted financial news and publishing company serving private and public entities, to assist with its corporate communications strategy. LIXTE Biotechnology is a clinical-stage pharmaceutical company developing differentiated cancer therapies built […]
InvestorNewsBreaks – Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK
January 8, 2026
Lixte Biotechnology Holdings (NASDAQ: LIXT) announced an expansion of its collaboration with The University of Texas MD Anderson Cancer Center and pharmaceutical manufacturer GSK on an ongoing clinical trial evaluating its proprietary compound LB-100 in combination with GSK’s Dostarlimab for the treatment of ovarian clear cell cancer. The trial, initiated in January 2024 and led […]
InvestorNewsBreaks – Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) Announces $4.3 Million Registered Direct Offering Priced at Market
January 7, 2026
Lixte Biotechnology Holdings (NASDAQ: LIXT) entered into definitive agreements in a registered direct offering with accredited investors for the purchase and sale of approximately $4.3 million of Common Stock and pre-funded and investor warrants at a price of $4.09 per Common Unit, priced at the market under Nasdaq rules. The offering comprised 1,051,342 Common Units or Pre-Funded Units, each consisting […]
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is ‘One to Watch’
January 7, 2026
LIXTE Biotechnology Holdings (NASDAQ: LIXT) is a clinical-stage pharmaceutical company developing differentiated cancer therapies built around a novel biological target. Rather than introducing standalone treatments, the company is focused on advancing a first-in-class approach designed to enhance the effectiveness of established cancer therapies, addressing persistent challenges that continue to limit outcomes in oncology. LIXTE’s work centers […]
InvestorNewsBreaks – Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FSE: GDT0) Looking to Carve out Significant Market Share Amidst Regulatory Push for Secure Communications
December 26, 2023
Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FSE: GDT0) is a cybersecurity and internet privacy provider of Swiss-hosted solutions for secure communications and data management. The company is positioned amid the U.S. Securities and Exchange Commission’s (“SEC”) unrelenting push and crackdown on Wall Street to offer a secure, easy-to-use and transparent messaging solution. “The SEC […]
Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0) Offering SekurMessenger, its Encrypted Messenger App, Amid SEC FINRA Violations Crackdown
November 21, 2023
Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0), a cybersecurity and internet privacy provider of Swiss-hosted solutions for secure communications and secure data management, is offering a secure, easy-to-use, and transparent messaging solution to Wall Street companies amid the U.S. Securities and Exchange Commission (“SEC”) crackdowns. SekurMessenger is an encrypted messaging service that offers […]
Lixte Biotechnology Holdings Inc. (NASDAQ: LIXT) Featured in Coverage of Sidoti’s Virtual Microcap Conference
May 13, 2021
Lixte Biotechnology Holdings Inc. (NASDAQ: LIXT) is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases. A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off. The company’s innovative approach encourages cancer […]